130 related articles for article (PubMed ID: 1394227)
1. Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential.
Mullen CA; Coale MM; Levy AT; Stetler-Stevenson WG; Liotta LA; Brandt S; Blaese RM
Cancer Res; 1992 Nov; 52(21):6020-4. PubMed ID: 1394227
[TBL] [Abstract][Full Text] [Related]
2. Tumor cells engineered to express interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell model.
Ledda MF; Adris S; Bravo AI; Bover L; Carbone C; Paleolog E; Mordoh J; Chernajovsky Y; Podhajcer OL
Cell Mol Biol (Noisy-le-grand); 1996 Jul; 42(5):769-78. PubMed ID: 8832108
[TBL] [Abstract][Full Text] [Related]
3. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity.
McBride WH; Thacker JD; Comora S; Economou JS; Kelley D; Hogge D; Dubinett SM; Dougherty GJ
Cancer Res; 1992 Jul; 52(14):3931-7. PubMed ID: 1617669
[TBL] [Abstract][Full Text] [Related]
4. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
[TBL] [Abstract][Full Text] [Related]
5. Involvement of immune responses in the eradication of IL-1 alpha gene-transduced tumour cells: mechanisms of tumour rejection and immunotherapeutical implications.
Apte RN; Douvdevani A; Zoller M; White RM; Dvorkin T; Shimoni N; Huleihel M; Fima E; Hacham M; Voronov E
Folia Biol (Praha); 1994; 40(1-2):1-18. PubMed ID: 7958060
[TBL] [Abstract][Full Text] [Related]
6. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T cells and prevents the development of unresponsiveness.
Zier KS; Salvadori S; Cronin KC; Gansbacher B
Cancer Gene Ther; 1994 Mar; 1(1):43-50. PubMed ID: 7621237
[TBL] [Abstract][Full Text] [Related]
8. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
9. Effects of IL-1 molecules on growth patterns of 3-MCA-induced cell lines: an interplay between immunogenicity and invasive potential.
Voronov E; Reich E; Dotan S; Dransh P; Cohen I; Huszar M; Fogel M; Kleinman HK; White RM; Apte RN
J Immunotoxicol; 2010 Mar; 7(1):27-38. PubMed ID: 20001788
[TBL] [Abstract][Full Text] [Related]
10. Insertion of the IL-2 gene decreases tumorigenicity of murine fibrosarcoma.
Kuśnierczyk H; Załecki P; Pajtasz-Piasecka E; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1998; 46(4):259-65. PubMed ID: 9779293
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice.
Tartour E; Fossiez F; Joyeux I; Galinha A; Gey A; Claret E; Sastre-Garau X; Couturier J; Mosseri V; Vives V; Banchereau J; Fridman WH; Wijdenes J; Lebecque S; Sautès-Fridman C
Cancer Res; 1999 Aug; 59(15):3698-704. PubMed ID: 10446984
[TBL] [Abstract][Full Text] [Related]
12. Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes.
Mullen CA; Petropoulos D; Lowe RM
Cancer Res; 1996 Mar; 56(6):1361-6. PubMed ID: 8640826
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells.
Porgador A; Tzehoval E; Katz A; Vadai E; Revel M; Feldman M; Eisenbach L
Cancer Res; 1992 Jul; 52(13):3679-86. PubMed ID: 1617640
[TBL] [Abstract][Full Text] [Related]
14. Immune response to progressor variants derived from transfection of an ultraviolet radiation-induced C3H mouse regressor tumor cell line with activated Harvey-ras oncogene.
Kaba DS; Pierceall WE; Price JE; Ananthaswamy HN
Cancer Res; 1990 Jun; 50(11):3159-66. PubMed ID: 2185882
[TBL] [Abstract][Full Text] [Related]
15. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
Kawamura K; Bahar R; Natsume W; Sakiyama S; Tagawa M
Cancer Gene Ther; 2002 Jan; 9(1):109-15. PubMed ID: 11916240
[TBL] [Abstract][Full Text] [Related]
16. Functional defects are associated with abnormal signal transduction in T cells of mice inoculated with parental but not IL-2 secreting tumor cells.
Salvadori S; Gansbacher B; Zier K
Cancer Gene Ther; 1994 Sep; 1(3):165-70. PubMed ID: 7542552
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases.
Nanni P; Rossi I; De Giovanni C; Landuzzi L; Nicoletti G; Stoppacciaro A; Parenza M; Colombo MP; Lollini PL
Cancer Res; 1998 Mar; 58(6):1225-30. PubMed ID: 9515809
[TBL] [Abstract][Full Text] [Related]
18. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells.
Tasaki K; Yoshida Y; Maeda T; Miyauchi M; Kawamura K; Takenaga K; Yamamoto H; Kouzu T; Asano T; Ochiai T; Sakiyama S; Tagawa M
Cancer Gene Ther; 2000 Feb; 7(2):247-54. PubMed ID: 10770633
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis.
Huang S; Xie K; Bucana CD; Ullrich SE; Bar-Eli M
Clin Cancer Res; 1996 Dec; 2(12):1969-79. PubMed ID: 9816156
[TBL] [Abstract][Full Text] [Related]
20. Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells.
Ferrantini M; Proietti E; Santodonato L; Gabriele L; Peretti M; Plavec I; Meyer F; Kaido T; Gresser I; Belardelli F
Cancer Res; 1993 Mar; 53(5):1107-12. PubMed ID: 8439955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
